Should You Be Tested?
The American Lung Association estimates that approximately 100,000 people in the United States suffer from AAT deficiency.*1 Up to 95% of those with AAT deficiency are undiagnosed.2
*Also known as Alpha-1, alpha-1 antitrypsin deficiency, AATD, A1-PI deficiency, alpha-1 antiprotease deficiency, A1AD, or hereditary or genetic emphysema.
Testing for Alpha-1 is recommended when you have symptoms of Alpha-1, or if a family member has been diagnosed with Alpha-1. Testing for AAT deficiency is as easy as a simple finger-stick blood test.
Use our convenient interactive symptom checker to see if you might be at risk.
What are the symptoms related to AAT deficiency?ATS/ERS Standards
"It is recommended that all subjects with COPD or asthma characterized by incompletely reversible air flow obstruction should be tested once for AAT deficiency."3
Download a printable version of Should You Be Tested?
ARALAST [Alpha1-Proteinase Inhibitor (Human)] is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.
Please review the Important Safety Information and the Full Prescribing Information
- American Lung Association. Alpha-1 related emphysema. Available at http://www.lungusa.org/site/pp.asp?c=dvLUK9O0E&b=35014#who. Accessed August 2, 2004.
- Wencker M. Screening for alpha1-PI deficiency in patients with lung diseases. Respir Med. 2000;94(suppl C):S16-S17.
- Adapted from the American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with AAT deficiency. Am J Respir Crit Care Med. 2003; 168:818-900.
 |
To view PDF, you will need Adobe® Acrobat® Reader® software. |
